Alphamab Oncology (stock code: 9966.HK) today announced that the results from a Phase I clinical study (JSKN016-101, NCT06592417) of its first-in-class TROP2/HER3 bispecific antibody-drug conjugate ...

This new platform bridges the gap between routine patient care and clinical research, creating a single, comprehensive wound ...

PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the ...

Health technology company Seqster announced Thursday the launch of its new 1-Click Sites platform, tapping BioIVT as its ...

Overall, TherVacB was found to be safe, well-tolerated, and highly immunogenic among the healthy study participants.

JOURNAVX met the primary endpoint by demonstrating statistically significant superior reduction in pain vs placebo. 1,b JOURNAVX did not meet the first key secondary endpoint that hypothesized ...

Identification of Individuals With Hereditary Cancer Risk Through Multiple Data Sources: A Population-Based Method Using the GARDE Platform and The Utah Population Database The study included patients ...

Worldwide becomes first CRO to implement Medidata Plus, gaining access to enterprise-level AI across the Medidata Study, Data ...

FDA officials said an internal analysis found results were not submitted for nearly 30% of studies “highly likely” to fall ...

The Food and Drug Administration will announce on Monday that it has sent over 2,200 letters pressing drug manufacturers, ...